P 10294
Latest Information Update: 07 Sep 1998
Price :
$50 *
At a glance
- Originator Aventis
- Class Anti-inflammatories; Antipsoriatics
- Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Skin disorders
Most Recent Events
- 07 Sep 1998 No-Development-Reported for Inflammation in USA (Topical)
- 07 Sep 1998 No-Development-Reported for Skin disorders in USA (Topical)
- 18 Sep 1996 Preclinical development for Inflammation in USA (Topical)